Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 24, 2015
Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable LinkerBrooke M Rock, Mark E Tometsko, Sonal K Patel, et al.
Bioconjugate Chemistry|January 20, 2005
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphomaKevin J Hamblett, Oliver W Press, Damon L Meyer, et al.
Bioconjugate Chemistry|May 16, 2002
A streptavidin-biotin binding system that minimizes blocking by endogenous biotinKevin J Hamblett, Brian B Kegley, Don K Hamlin, et al.
Protein Engineering, Design & Selection : PEDS|April 29, 2006
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachmentCharlotte F McDonagh, Eileen Turcott, Lori Westendorf, et al.
Molecular Pharmaceutics|June 2, 2016
Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and TolerabilityKevin J Hamblett, Tiep Le, Brooke M Rock, et al.
Bioconjugate Chemistry|September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Molecular Cancer Therapeutics|May 2, 2015
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing GlioblastomaKevin J Hamblett, Carl J Kozlosky, Sophia Siu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateKevin J Hamblett, Peter D Senter, Dana F Chace, et al.
Cancer Research|December 4, 2015
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the CytoplasmKevin J Hamblett, Allison P Jacob, Jesse L Gurgel, et al.
Pageof 1